Abstract
Epidemiological studies have suggested that obstructive sleep apnea syndrome (OSAS) may increase the risk of developing cognitive impairment. In patients with Alzheimer’s disease (AD), the prevalence of OSAS is much higher than that expected in cognitively healthy subjects. A deeper knowledge of the pathophysiological link between OSAS and AD and the demonstration that OSAS may directly influence the development of cognitive alterations, would increase prevention and treatment strategies for AD patients. In this article, we discuss the evidence of the association between OSAS and dementia. Moreover, we present data about the functional and anatomic cerebral changes induced by OSAS and the possible effects on cognitive activities and on AD pathogenesis. The possibility to positively influence cognitive impairment by OSAS treatment will be also discussed.
Keywords: Alzheimer’s disease, cognitive deterioration, continuous positive airway pressure, obstructive sleep apnea syndrome, pathophysiology, preventive strategies.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
Volume: 15 Issue: 6
Author(s): Laura Buratti, Simona Luzzi, Cristina Petrelli, Sara Baldinelli, Giovanna Viticchi, Leandro Provinciali, Claudia Altamura, Fabrizio Vernieri and Mauro Silvestrini
Affiliation:
Keywords: Alzheimer’s disease, cognitive deterioration, continuous positive airway pressure, obstructive sleep apnea syndrome, pathophysiology, preventive strategies.
Abstract: Epidemiological studies have suggested that obstructive sleep apnea syndrome (OSAS) may increase the risk of developing cognitive impairment. In patients with Alzheimer’s disease (AD), the prevalence of OSAS is much higher than that expected in cognitively healthy subjects. A deeper knowledge of the pathophysiological link between OSAS and AD and the demonstration that OSAS may directly influence the development of cognitive alterations, would increase prevention and treatment strategies for AD patients. In this article, we discuss the evidence of the association between OSAS and dementia. Moreover, we present data about the functional and anatomic cerebral changes induced by OSAS and the possible effects on cognitive activities and on AD pathogenesis. The possibility to positively influence cognitive impairment by OSAS treatment will be also discussed.
Export Options
About this article
Cite this article as:
Buratti Laura, Luzzi Simona, Petrelli Cristina, Baldinelli Sara, Viticchi Giovanna, Provinciali Leandro, Altamura Claudia, Vernieri Fabrizio and Silvestrini Mauro, Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia, CNS & Neurological Disorders - Drug Targets 2016; 15 (6) . https://dx.doi.org/10.2174/1871527315666160518123930
DOI https://dx.doi.org/10.2174/1871527315666160518123930 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Association of Prolyl Oligopeptidase with Conventional Neurotransmitters in the Brain
CNS & Neurological Disorders - Drug Targets Amendatory Effect of Flavonoids in Alzheimer's Disease Against Mitochondrial Dysfunction
Current Drug Targets Late-life Depression and Alzheimer Disease: A Potential Synergy of the Underlying Mechanisms
Current Medicinal Chemistry Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Chronobiological Approaches to Alzheimers Disease
Current Alzheimer Research Amyloid-β Immunotherapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Dementia from a Childs Perspective
Current Aging Science Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Current Drug Metabolism Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry The Role of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke: From Laboratory to Clinics
Current Vascular Pharmacology Reactive Oxygen Species, Redox Signaling and Neuroinflammation in Alzheimer's Disease: The NF-κB Connection
Current Topics in Medicinal Chemistry A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued) Hormonal Control of the Neuropeptide Y System
Current Protein & Peptide Science Commentary [Research Highlights (Making Sense Out of Antisense in Huntington’s Disease)]
CNS & Neurological Disorders - Drug Targets Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Current Pharmaceutical Design Dietary Patterns in Alzheimers Disease and Cognitive Aging
Current Alzheimer Research The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease
Current Pharmaceutical Design The Critical Period for Neuroprotection by Estrogen Replacement Therapy and the Potential Underlying Mechanisms
Current Neuropharmacology Pharmacological Effects of Turmeric on Learning, Memory and Expression of Muscarinic Receptor Genes (M1, M3 and M5) in Stress-induced Mouse Model
Current Drug Targets